Albumin-bound paclitaxel in solid tumors: clinical development and future directions.
Albumin-bound paclitaxel in solid tumors: clinical development and future directions.
复制标题
DOI：
10.2147/dddt.s88023
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Niu J
中科院分区：
文献类型：
--
作者：
Kundranda MN;Niu J
白蛋白结合紫杉醇(NaB-Paclitaxel)是紫杉醇的一种无溶剂制剂，最初是在十多年前开发的，目的是克服标准紫杉醇配方中使用的溶剂的毒性，并潜在地提高疗效。NAB-紫杉醇比溶剂型紫杉醇更具优势，因为它能够将更大剂量的紫杉醇输送到肿瘤细胞，并减少严重毒性反应的发生率，包括严重的过敏反应。到目前为止，NAB-紫杉醇在美国已被用于治疗三种实体肿瘤。它于2005年首次被批准用于治疗转移性乳腺癌，随后在2012年被批准用于局部晚期或转移性非小细胞肺癌，最近一次是在2013年被批准用于转移性胰腺癌。NAB-紫杉醇也在研究中，用于治疗其他一些实体肿瘤。本文重点介绍了NaB-紫杉醇在实体瘤中的主要临床疗效和安全性结果，讨论了正在进行的试验，这些试验可能会为NAB-紫杉醇的适应症扩展到其他实体肿瘤提供新的数据，并为NaB-紫杉醇在实践中的使用提供了临床前景。
Albumin-bound paclitaxel (nab-paclitaxel) is a solvent-free formulation of paclitaxel that was initially developed more than a decade ago to overcome toxicities associated with the solvents used in the formulation of standard paclitaxel and to potentially improve efficacy. Nab-paclitaxel has demonstrated an advantage over solvent-based paclitaxel by being able to deliver a higher dose of paclitaxel to tumors and decrease the incidence of serious toxicities, including severe allergic reactions. To date, nab-paclitaxel has been indicated for the treatment of three solid tumors in the USA. It was first approved for the treatment of metastatic breast cancer in 2005, followed by locally advanced or metastatic non-small-cell lung cancer in 2012, and most recently for metastatic pancreatic cancer in 2013. Nab-paclitaxel is also under investigation for the treatment of a number of other solid tumors. This review highlights key clinical efficacy and safety outcomes of nab-paclitaxel in the solid tumors for which it is currently indicated, discusses ongoing trials that may provide new data for the expansion of nab-paclitaxel’s indications into other solid tumors, and provides a clinical perspective on the use of nab-paclitaxel in practice.